Record Details

APIXABAN IN THE TREATMENT OF ATRIAL FIBRILLATION: RANDOMIZED TRIALS AND EVERYDAY CLINICAL PRACTICE

Atherothrombosis Journal

View Archive Info
 
 
Field Value
 
Title APIXABAN IN THE TREATMENT OF ATRIAL FIBRILLATION: RANDOMIZED TRIALS AND EVERYDAY CLINICAL PRACTICE
АПИКСАБАН В ЛЕЧЕНИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: РАНДОМИЗИРОВАННЫЕ ИССЛЕДОВАНИЯ И ПОВСЕДНЕВНАЯ КЛИНИЧЕСКАЯ ПРАКТИКА
 
Creator O. Shakhmatova O.; Institute of Cardiology named after A.L. Myasnikov, Russian Cardiology Research and Production Complex, MoH RF, Moscow
E. Panchenko P.; Institute of Cardiology named after A.L. Myasnikov, Russian Cardiology Research and Production Complex, MoH RF, Moscow
О. Шахматова О.; НИИ кардиологии им. А.Л. Мясникова РКНПК МЗ РФ
Е. Панченко П.; НИИ кардиологии им. А.Л. Мясникова РКНПК МЗ РФ
 
Subject apixaban; eliquis; atrial fibrillation; cardioversion; catheter ablation; routine practice; gastrointestinal bleeding; the elderly
апиксабан; эликвис; фибрилляция предсердий; кардиоверсия; катетерная абляция; рутинная практика; желудочно-кишечные кровотечения; пожилые
 
Description Apixaban is the only NOA the administration of which is associated with a reduction in the incidence of both stroke and major bleeding. Therefore, apixaban is the drug of choice in patients with non-valvular AF, including elderly patients, patients with a high risk of bleeding complications, as well as in patients with impaired renal function. In clinical practice, the efficacy and safety of apixaban are not inferior to those obtained in the ARISTOTLE trial. Apixaban is safe when used during cardioversion and catheter ablation. The results of pre-clinical studies provide implications for further investigation into the possibility of administration of apixaban in patients with «valvular» AF.  
Апиксабан является единственным НОАК, применение которого ассоциируется со снижением частоты как инсультов, так и больших кровотечений. Соответственно, апиксабан является препаратом выбора у пациентов с неклапанной ФП, в т. ч. у пожилых пациентов, больных с высоким риском геморрагических осложнений, а также у пациентов с нарушенной почечной функцией. В реальной клинической практике показатели эффективности и безопасности применения апиксабана не уступают таковым, полученным в исследовании ARISTOTLE. Апиксабан безопасен при использовании во время кардиоверсии и катетерной абляции. Результаты доклинического исследования дают основание для дальнейшего изучения возможности применения апиксабана у пациентов с «клапанной» ФП.  
 
Publisher «REMEDIUM GROUP» Ltd.
 
Contributor —
—
 
Date 2017-05-31
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
—
 
Format application/pdf
 
Identifier http://www.aterotromboz.ru/jour/article/view/110
10.21518/2307-1109-2017-1-67-77
 
Source Atherothrombosis Journal; № 1 (2017); 67-77
Атеротромбоз; № 1 (2017); 67-77
2307-1109
10.21518/2307-1109-2017-1
 
Language rus
 
Relation http://www.aterotromboz.ru/jour/article/view/110/154
Fauchier L, Philippart R, Clementy N, et al.How to define valvular atrial fibrillation? Arch Cardiovasc Dis, 2015, 108: 530–539.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med, 1987, 147: 1561–1564.
P Kirchhof, S Benussi, D Kotecha, etal. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. doi: 10.1093/eurheartj/ehw210.
Evaluation of prescribing with NOACs vs VKAs in nonvalvular AF. Доклад Sylvia Haas на Европейском Конгрессе Кардиологов 2016, Рим. https: //www.youtube.com/watch?v = xSrsxJd7tJM.
Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2017 Feb 15, 103(4): 307-314. doi: 10.1136/heartjnl-2016-309832. Epub 2016 Sep 19.6.www.imshealth.com.
Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med, 2011, 365: 981-992.
Wallentin L, Lopes RD, Hanna M et al. Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted INR Control for Stroke Prevention in Atrial Fibrillation. Circulation, 2013, 127: 2166-2176.
Easton JD, Lopes RD, Bahit M, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. The Lancet Neurology, 2012, 11(6): 503-511.
Alexander JH, Lopes RD, Thomas L et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, 2014, 35: 224–232.
Bahit MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart Online First, published on October 24, 2016 as 10.1136/heartjnl-2016-309901.
Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety ofapixaban in patients after cardioversion for atrial fibrillation: insightsfrom the ARISTOTLE trial (Apixaban for Reduction in Stroke andOther Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol, 2014, 63: 1082–7.
Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol, 2014 Oct 14, 64(15): 1541-50. doi:10.1016/j.jacc.2014.07.967.
Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J, 2015 May 21, 36(20): 1264-72. doi:10.1093/eurheartj/ehu463.
Focks JJ, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ, 2016, 353: i2868. Published online 2016 Jun 15. doi: 10.1136/bmj.i2868.
Melloni C, Dunning A, Granger CB et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and active cancer: insights from the ARISTOTLE trial. Paper presented at Congress of the European-Society-of-Cardiology (ESC), AUG 27-31, 2016, Rome, ITALY, pp. 234-234.
Xavier D, Hanna M, Wallentin L et al. Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with war-farin: insights from the ARISTOTLE trial. Paper presented at Congress of the European-Society-of-Cardiology (ESC), AUG 27-31, 2016, Rome, ITALY, pp. 507-507.
Westenbrink B, Alings M, Granger CB.,et al. Anemia Is Associated With Bleeding and Mortality, but Not Stroke, in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. American Heart Journal, 2016. doi: 10.1016/j.ahj.2016.12.008.
Hu PT, Lopes RD, Stevens SR, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. JAHA, 2017, 6: e004699. originally published January 17, 2017. https: //doi.org/10.1161/JAHA.116.004699.
Guimara~es PO, Wojdyla DM, Alexander JH, et al. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol, 2017 Jan 15, 227: 443-449. doi:10.1016/j.ijcard.2016.11.014.
Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J, 2012, 33(22): 2821-2830.
Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol, 2016, 1(4): 451-460. doi: 10.1001/jamacardio.2016.1170.
Лукьянов М.М., Бойцов С.А., Якушин C.C. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным регистра кардиоваскулярных заболеваний РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии, 2014, 10(4): 366-77.24)
Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol, 2013 Dec 10, 170(2): 215-20. doi:10.1016/j.ijcard.2013.10.062.
Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ, 2016, 353: i3189.
Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non- valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost, 2016 Oct 28, 116(5): 975-986.
Lamberts M, Staerk L, Olesen JB, et al. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation:Contemporary Findings in Real-Life Danish Patients. J Am Heart Assoc, 2017 Feb 14, 6(2): e004517. doi:10.1161/JAHA.116.004517.
Deitelzweig S, Bruno A, Trocio J, et al. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Current Medical Research And Opinion, 2016, 32(3).
Raschi E, Bianchin M, Ageno W, et al. Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Saf, 2016, 39: 1175–1187.
Freedman B, Potpara TS, Lip GYH. Stroke prevention in atrial fibrillation. The Lancet, 2016, 388(10046): 806-817.
Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fibrillation: part 1. Eur Heart J. doi:10.1093/eurheartj/ehv643. (Epub 4 Feb 2016).
Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fibrillation: part 2. Eur Heart J, doi:10.1093/eurheartj/ehw069. (Epub 4 Feb 2016).
Ukaigwe A, Shrestha P, Karmacharya P, et al. Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists inpatients undergoing catheter ablation for atrial fibrillation. J Interv Card Electrophysiol, 2017 Mar, 48(2): 223-233. doi: 10.1007/s10840-016-0195-5.
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015 Oct, 17(10): 1467-507. doi:10.1093/europace/euv309.
Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol, 2016 May, 56(5): 628-36. doi: 10.1002/jcph.628.
Lester PA, Coleman DM, Diaz JA, et al.ApixabanVersusWarfarinfor Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. https: //doi.org/10.1161/ATVBA-HA.116.308649. Arteriosclerosis, Thrombosis, and Vascular Biology. 2017, ATVBAHA.116.308649 Originally published February 23, 2017.
 
Rights Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access).